Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ricolinostat |
Synonyms | |
Therapy Description |
Ricolinostat (ACY-1215) is a selective inhibitor of HDAC6, which may decrease tumor cell viability and reduce tumor growth, alone or in combination with other agents (PMID: 22262760, PMID: 27926524, PMID: 32705192). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ricolinostat | ACY-1215 | HDAC Inhibitor 45 | Ricolinostat (ACY-1215) is a selective inhibitor of HDAC6, which may decrease tumor cell viability and reduce tumor growth, alone or in combination with other agents (PMID: 22262760, PMID: 27926524, PMID: 32705192). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01323751 | Phase Ib/II | Bortezomib + Dexamethasone Ricolinostat | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma | Completed | USA | 0 |
NCT02091063 | Phase Ib/II | Ricolinostat | ACY-1215 for Relapsed/Refractory Lymphoid Malignancies | Terminated | USA | 0 |